Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness

NCT03321045 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: [89Zr]-Df-Trastuzumab
DIAGNOSTIC_TEST: PET/MRI Imaging

Sponsor

University of Alabama at Birmingham